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Background
Our hypothesis is that the replicating Ad4 vector
approach, may be the best strategy for an effective HIV-1
vaccine due to advantages of demonstrated clinical safety
and immunogenicity of both the Ad4 backbone and an
Ad4 H5N1 vector influenza vaccine evaluated in Phase 1.
Unlike other vectors, it can be bioengineered to express
full-length HIV-1 Env gp160. More than 50% of global
HIV-1 infections are caused by clade C viruses and there-
fore we initiated development of Ad4-Env160 vaccine
using an Env clade C sequence obtained from CHAVI.
Methods
The Ad4-Env viruses were evaluated for: 1) genetic stabi-
lity; 2) Env protein expression by Western blot analysis;
3) cell-surface Env recognition by broadly neutralizing
antibody (bnAb); and 4) immunogenicity in rabbits.
Results
Genetically stable Ad4 recombinant viruses were gener-
ated which expressed the Env gp120, gp140, and gp160
proteins. A549 cells infected with Ad4-Env160 virus
expressed cell-surface Env that was recognized by bnAb
specific for MPER, CD4bs, V2-V3 loop sequences. Follow-
ing immunization of rabbits, Env-specific binding antibo-
dies were induced as measured by ELISA; 160>140>120.
Conclusion
An Ad4 virus expressing full-length Env160 was generated
and evaluated for genetic stability, protein expression,
recognition by bnAb and immunogenicity. These results
represent substantial progress towards defining a replicat-
ing Ad4 vector, recombinant protein vaccine prime/boost
approach for HIV-1 that could eventually undergo clinical
testing. Funding: NIH/NIAID SBIR 1R43AI091546-01;
NIH/NIAID Contract No. HHSN266200400045C.
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